NASDAQ:DNLI Denali Therapeutics Q3 2025 Earnings Report $23.57 +0.46 (+1.99%) Closing price 07/27/2026 04:00 PM EasternExtended Trading$24.18 +0.61 (+2.61%) As of 07/27/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Denali Therapeutics EPS ResultsActual EPS-$0.74Consensus EPS -$0.76Beat/MissBeat by +$0.02One Year Ago EPS-$0.63Denali Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.00 millionBeat/MissN/AYoY Revenue GrowthN/ADenali Therapeutics Announcement DetailsQuarterQ3 2025Date11/6/2025TimeBefore Market OpensConference Call DateThursday, November 6, 2025Conference Call Time7:00AM ETUpcoming EarningsDenali Therapeutics' Q2 2026 earnings is estimated for Monday, August 10, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Denali Therapeutics Earnings HeadlinesDenali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026July 27 at 4:01 PM | globenewswire.comGoldman Sachs Remains a Buy on Denali Therapeutics (DNLI)July 23, 2026 | theglobeandmail.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required. | Stansberry Research (Ad)Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval?July 23, 2026 | finance.yahoo.comDenali Therapeutics (DNLI) Heads To AAIC, Is The Stock Already Pricey?July 23, 2026 | finance.yahoo.comDenali Therapeutics to Give Opening Plenary Address at Alzheimer’s Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic ...July 9, 2026 | markets.businessinsider.comSee More Denali Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Denali Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Denali Therapeutics and other key companies, straight to your email. Email Address About Denali TherapeuticsDenali Therapeutics (NASDAQ:DNLI) is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients. The company is also advancing modulators of progranulin for frontotemporal dementia and exploring novel approaches to lysosomal storage disorders. Denali has entered strategic collaborations with established industry partners to accelerate clinical development, most notably with Biogen for Alzheimer’s and Sanofi for lysosomal programs. Founded in 2015 by industry veteran Stefan Oehlén and headquartered in South San Francisco, Denali maintains research sites in Cambridge, Massachusetts, and has expanded its organization to support global clinical trials. The company went public in 2019, and its leadership is led by Chief Executive Officer Ryan Watts, whose background in finance and biotech supports Denali’s capital strategy and pipeline advancement. Denali Therapeutics conducts its research and clinical operations primarily in the United States while pursuing regulatory approvals and trial sites globally. The company’s goal is to address unmet needs in neurodegeneration by bringing forward differentiated therapies that can slow or stop disease progression, offering new hope for patients and families affected by these challenging disorders.View Denali Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AMD’s AI Bubble Could Burst Into Explosive UpsideRefiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?Atlassian’s AI Pivot Is Starting to Challenge Wall Street’s Bear CaseVerizon May Be an AI Infrastructure Stock Hiding in Plain SightApple’s Earnings Setup Puts Its Record Rally and AI Patience to the TestMarketBeat Week in Review – 07/20- 07/24Telecom Earnings Reveal a Sector That Finally Looks Healthier Upcoming Earnings Agnico Eagle Mines (7/29/2026)General Dynamics (7/29/2026)L3Harris Technologies (7/29/2026)Automatic Data Processing (7/29/2026)Amphenol (7/29/2026)ARM (7/29/2026)Fortinet (7/29/2026)Lam Research (7/29/2026)Meta Platforms (7/29/2026)Microsoft (7/29/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
